News

Topline results showed that the drug didn’t meet the primary endpoints of superior overall survival, compared with standard of care.

Despite the good news, there is still “disappointment surrounding the restrictions on prescribing cannabis-based drugs in the UK.”

The data marks an important milestone for CKD-related anaemia patients, as it is the “first innovation of its kind for this market in many years.”

The treatment fell short of its primary endpoint of increase in ongoing pregnancy rate at 10 weeks.

Keytruda is predicted to be the best-selling drug by annual revenue in 2023.

The MAAs are supported by data from Phase I, II and III clinical studies.

The jointly-sponsored study aims to validate PredictSURE IBD – the company’s first prognostic test for inflammatory bowel disease, in the US market.

Currently, there are limited treatment options available that can prolong the lives of metastatic colorectal cancer patients.

Bemcentinib, formerly known as BGB324, is a potentially first-in-class selective AXL inhibitor.

The partnership will enable Vifor to identify new targets for renal therapies to bolster the company’s pipeline.

Despite the legislation of cannabis being passed a year ago, it remains out of reach for the vast majority of patients.

The drug has been approved and marketed in Europe as Ziextenzo since 2018.

The initiative provides support in developing systems to improve health and social care evidence-based decision making.

The new platform is called ActNow, and people “get back to the comfort of their own home quicker.”